INDICATION
JULUCA is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for ≥6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of JULUCA. JULUCA should be taken with a meal
ARVs=antiretrovirals.
INDICATION
JULUCA is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for ≥6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of JULUCA. JULUCA should be taken with a meal
ARVs=antiretrovirals.
Discover JULUCA
148-Week Long-Term Data
Learn more about the virologic efficacy, safety, and resistance data for JULUCA
A deeper look at JULUCA
REQUEST A ViiV REPRESENTATIVE
Have questions about JULUCA? Speak with a ViiV Representative in person

Patient Support
Learn more about the programs available for prescribed patients
